Remogliflozin etabonate (GSK 189075A, GSK 189075) is an SGLT2 inhibitor, the prodrug of regaliflozin. Remogliflozin inhibits the sodium-glucose transporter (SGLT), which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood sugar to be excreted from the urine.

442201-24-3

C26H38N2O9

522.59

GSK 189075A;GSK189075A;GSK 189075;GSK-189075A;GSK189075;GSK-189075;Remogliflozin etabonate

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years